Matrix control of pancreatic cancer: New insights into fibronectin signaling

被引:94
作者
Topalovski, Mary [1 ,2 ]
Brekken, Rolf A. [1 ,2 ,3 ,4 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Div Surg Oncol, Dallas, TX 75390 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA
关键词
Pancreatic cancer; Fibronectin; Extracellular matrix; Chemoresistance; Metastasis; Integrin; FOCAL ADHESION KINASE; TUMOR-GROWTH; STELLATE CELLS; TYROSINE-PHOSPHORYLATION; INTEGRIN ALPHA-5-BETA-1; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; TENASCIN-C; TGF-BETA; ANGIOGENESIS;
D O I
10.1016/j.canlet.2015.12.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDA) is a highly metastatic disease that resists most current therapies. A defining characteristic of PDA is an intense fibrotic response that promotes tumor cell invasion and chemoresistance. Efforts to understand the complex relationship between the tumor and its extra cellular network and to therapeutically perturb tumor-stroma interactions are ongoing. Fibronectin (FN), a provisional matrix protein abundant in PDA stroma but not normal tissues, supports metastatic spread and chemoresistance of this deadly disease. FN also supports angiogenesis, which is required for even hypovascular tumors such as PDA to develop and progress. Targeting components of the tumor stroma, such as FN, can effectively reduce tumor growth and spread while also enhancing delivery of chemotherapy. Here, we review the molecular mechanisms by which FN drives angiogenesis, metastasis and chemoresistance in PDA. In light of these new findings, we also discuss therapeutic strategies to inhibit FN signaling. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:252 / 258
页数:7
相关论文
共 118 条
  • [1] Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma
    Aguilera, Kristina Y.
    Rivera, Lee B.
    Hur, Hoon
    Carbon, Juliet G.
    Toombs, Jason E.
    Goldstein, Courtney D.
    Dellinger, Michael T.
    Castrillon, Diego H.
    Brekken, Rolf A.
    [J]. CANCER RESEARCH, 2014, 74 (04) : 1032 - 1044
  • [2] FIBRONECTIN AND INTEGRINS IN INVASION AND METASTASIS
    AKIYAMA, SK
    OLDEN, K
    YAMADA, KM
    [J]. CANCER AND METASTASIS REVIEWS, 1995, 14 (03) : 173 - 189
  • [3] Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
    Alvarez, R.
    Musteanu, M.
    Garcia-Garcia, E.
    Lopez-Casas, P. P.
    Megias, D.
    Guerra, C.
    Munoz, M.
    Quijano, Y.
    Cubillo, A.
    Rodriguez-Pascual, J.
    Plaza, C.
    de Vicente, E.
    Prados, S.
    Tabernero, S.
    Barbacid, M.
    Lopez-Rios, F.
    Hidalgo, M.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (08) : 1677 - 1678
  • [4] AOTA S, 1994, J BIOL CHEM, V269, P24756
  • [5] Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
    Bachem, MG
    Schünemann, M
    Ramadani, M
    Siech, M
    Beger, H
    Buck, A
    Zhou, SX
    Schmid-Kotsas, A
    Adler, G
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : 907 - 921
  • [6] Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins
    Bader, BL
    Rayburn, H
    Crowley, D
    Hynes, RO
    [J]. CELL, 1998, 95 (04) : 507 - 519
  • [7] Natural killer cells in innate immunity and cancer
    Becknell, Brian
    Caligiuri, Michael A.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2008, 31 (08) : 685 - 692
  • [8] Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731
  • [9] Developments in the treatment of early NSCLC: when to use chemotherapy
    Besse, B.
    Le Chevalier, T.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 52 - 59
  • [10] Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits
    Bhaskar, Vinay
    Fox, Melvin
    Breinberg, Danna
    Wong, Melanie H-L
    Wales, Pauline E.
    Rhodes, Susan
    DuBridge, Robert B.
    Ramakrishnan, Vanitha
    [J]. INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 7 - 12